References
- Wollina U. Pyoderma gangrenosum–a review. Orphanet J Rare Dis. 2007;2:19.
- von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137(6):1000–1005.
- Su WP, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790–800.
- Jockenhöfer F, Wollina U, Salva KA, et al. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol. 2019;180(3):615–620.
- Maverakis E, Ma C, Shinkai K, et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a delphi consensus of international experts. JAMA Dermatol. 2018;154(4):461–466.
- Haag C, Hansen T, Hajar T, et al. Comparison of three diagnostic frameworks for pyoderma gangrenosum. J Invest Dermatol. 2020. DOI:10.1016/j.jid.2020.04.019.
- Ruocco E, Sangiuliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009;23(9):1008–1017.
- McKenzie F, Arthur M, Ortega-Loayza AG. Pyoderma gangrenosum: what do we know now? Curr Dermatol Rep. 2018;7(3):147–157.
- Langan SM, Groves RW, Card TR, et al. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012;132(9):2166–2170.
- Lu JD, Hobbs MM, Huang WW, et al. Identification and evaluation of outcome measurement instruments in pyoderma gangrenosum: a systematic review. Br J Dermatol. 2020. [ epub ahead of print]. DOI:10.1111/bjd.19027.
- Adachi Y, Kindzelskii AL, Cookingham G, et al. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol. 1998;111(2):259–268.
- Shore RN. Pyoderma gangrenosum, defective neutrophil chemotaxis, and leukemia. Arch Dermatol. 1976;112(12):1792–1793.
- Holt PJ, Davies MG, Saunders KC, et al. Pyoderma gangrenosum: clinical and laboratory findings in 15 patients with special reference to polyarthritis. Medicine (Baltimore). 1980;59(2):114–133.
- Bentley-Phillips CB, Cooper RC, Hallett AF. Pharmacological modulation of neutrophil phagocytic function in a patient with recurrent sepsis, pyoderma gangrenosum and impaired phagocytosis. Br J Dermatol. 1982;106(6):687–695.
- Marzano AV, Damiani G, Ceccherini I, et al. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol. 2017;176(6):1588–1598.
- Lukens JR, Vogel P, Johnson GR, et al. RIP1-driven autoinflammation targets IL-1α independently of inflammasomes and RIP3. Nature. 2013;498(7453):224–227.
- Wang EA, Steel A, Luxardi G, et al. Classic ulcerative pyoderma gangrenosum is a T cell-mediated disease targeting follicular adnexal structures: a hypothesis based on molecular and clinicopathologic studies. Front Immunol. 2017;8:1980.
- Antiga E, Maglie R, Volpi W, et al. T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum. Clin Exp Immunol. 2017;189(3):383–391.
- Kanni T, Zenker O, Habel M, et al. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis? Br J Dermatol. 2018;179(2):413–419.
- Camous L, Roumenina L, Bigot S, et al. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood. 2011;117(4):1340–1349.
- Rafail S, Kourtzelis I, Foukas PG, et al. Complement deficiency promotes cutaneous wound healing in mice. J Immunol. 2015;194(3):1285–1291.
- Ghias MH, Hyde MJ, Tomalin LE, et al. Role of the complement pathway in inflammatory skin diseases: a focus on Hidradenitis Suppurativa. J Invest Dermatol. 2020;140(3):531–6.e1.
- Grand D, Navrazhina K, Frew JW. Integrating complement into the molecular pathogenesis of Hidradenitis Suppurativa. Exp Dermatol. 2020;29(1):86–92.
- Giamarellos-Bourboulis EJ, Argyropoulou M, Kanni T. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab. British Journal of Dermatology. 2020;183:176–178.
- InflaRx. Efficacy and safety study of IFX-1 in patients with moderate to severe hidradenitis suppurativa (HS) (SHINE). NLM identifier: NCT03487276. [cited 2020 May 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03487276?term=IFX-1&draw=2&rank=4
- McKenzie F, Cash D, Gupta A, et al. Biologic and small-molecule medications in the management of pyoderma gangrenosum. J Dermatolog Treat. 2019;30(3):264–276.
- Ormerod AD, Thomas KS, Craig FE, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015;350:h2958.
- Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–509.
- Kolios AG, Maul JT, Meier B, et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol. 2015;173(5):1216–1223.
- Marzano AV, Ortega-Loayza AG, Heath M, et al. Mechanisms of inflammation in neutrophil-mediated skin diseases. Front Immunol. 2019;10:1059.
- Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20(1):34–50.
- Guo R, Riedemann NC. Treatment of inflammatory diseases with inhibitors of C5A activity. United States patent US 0061202 A1. 2020 Feb 27.
- Guo R, Riedemann NC. Treatment of C5A for the treatment of viral pneumonia. United States patent US 0202900 A1. 2019 Jul 4.
- InflaRx. Clinical assessment of safety and tolerability of the new monoclonal humanized antibody CaCP29. [cited 2020 May 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT01319903?term=IFX-1&draw=2&rank=9
- InflaRx. InflaRx reports additional analysis of the SHINE phase IIb results for IFX-1 in Hidradenitis Suppurativa. [cited 2020 Jul 6]. Available from: https://www.globenewswire.com/news-release/2019/07/18/1884908/0/en/InflaRx-Reports-Additional-Analysis-of-the-SHINE-Phase-IIb-Results-for-IFX-1-in-Hidradenitis-Suppurativa.html
- InflaRx. InflaRx announces positive initial data from ongoing phase IIa open label study with IFX-1 in patients suffering from pyoderma gangraenosum. [cited 2020 Aug 28]. Available from: www.inflarx.de/Home/Investors/Press-Releases/02-2020-InflaRx-Announces-Positive-Initial-Data-from-Ongoing-Phase-IIa-Open-Label-Study-with-IFX-1-in-Patients-Suffering-from-Pyoderma-Gangraenosum-.html
- Friduss SR, Sadoff WI, Hern AE, et al. Fatal pyoderma gangrenosum in association with C7 deficiency. J Am Acad Dermatol. 1992;27(2 Pt 2):356–359.